002294.SZ
002294.SZ
CNE100000FW8
SALUBRIS
Loading chart...

Company Profile

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.

Related stocks

000963.SZ
000963.SZ • China
HD MEDICINE
27.29 CNY
7.16B USD 1Y -34.6%
600085.SS
600085.SS • China
BEIJING TONG REN TANG CO
24.28 CNY
4.98B USD 1Y -29.3%
000999.SZ
000999.SZ • China
CR SANJIU
24.82 CNY
6.18B USD 1Y -12.3%
000423.SZ
000423.SZ • China
DEEJ
46.68 CNY
4.47B USD 1Y -1.3%
688192.SS
688192.SS • China
DIZAL PHARMACEUTICAL CO LTD
59.95 CNY
4.17B USD 1Y -15%
002262.SZ
002262.SZ • China
NHWA
21.74 CNY
3.3B USD 1Y -21.8%
6887.HK
6887.HK • China
SUNSHINE PHARMA
40.06 HKD
2.93B USD 1Y -16.6%
002773.SZ
002773.SZ • China
KHPG
20.66 CNY
2.85B USD 1Y -43.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
40.5% p.a.
Max Drawdown (5Y)
-56.7%
Sharpe Ratio (5Y)
-0.02
Beta Factor
-0.21
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 49.9 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -63.5% in the extended horizon.
ende